Market By Drug Type, Technology, Service, End-user, And Geography | Forecast 2019-2028
According to Triton, the Europe drug discovery market is predicted to record a significant growth at a CAGR of 6.21% over the forecast period 2019-2028.
Report scope can be customized per your requirements. Request For Customization
Countries studied in the
Europe drug discovery market are:
• Germany
• The United Kingdom
• France
• Spain
• Italy
• Russia
• Rest of Europe countries
Europe is a highly lucrative
market for drug discovery. The region has adopted the latest technologies for
the development of its healthcare system. Every year, 3.9 million people in the
region lose their lives due to cardiovascular disease, accounting for 45% of
the total deaths in the region. Also, the death rates due to stroke and
ischemic heart disease (IHD) is also significantly high in Central and Eastern
Europe. These factors have increased the demand for specialty medicines, which,
in turn, has fueled the demand for drug discovery. The increased demand
presents positive growth opportunities for the European drug discovery market.
The drug discovery market is
witnessing rapid growth in the United Kingdom. The European Lead Factory is a
major market driver of drug discovery in the region. It is a public-private
partnership approach that aims to accelerate drug discovery across Europe, by
linking innovative drug targets to high-quality compounds. Cancer Research UK
runs a program called “Small Molecule Drug Discovery Project Award” and funds
projects at all stages of drug discovery. However, there have been several
consequences of the Brexit for the effectiveness of pharmaceutical research in
the United Kingdom and Europe, which can restrain the growth of the drug
discovery market.
GlaxoSmithKline
LLC (GSK) is engaged in the R&D and production of pharmaceuticals,
vaccines, and consumer healthcare products for customers around the world. It
offers medicines and vaccines to treat a range of acute & chronic diseases
and respiratory diseases. It also offers OTC medicines and wellness, oral
health, nutrition, and skin health products. The company’s current R&D
efforts cover areas like HIV and infectious diseases, immuno-inflammation,
oncology, respiratory, and rare diseases. Formerly known as SmithKline Beecham
Corporation, GSK is headquartered in Middlesex, the United Kingdom.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. EUROPE
DRUG DISCOVERY MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. MARKET
DEFINITION
2.2. PORTER'S
FIVE FORCES MODEL
2.2.1. THREATS
OF NEW ENTRANTS
2.2.2. THREAT
OF SUBSTITUTE PRODUCTS
2.2.3. BARGAINING
POWER OF BUYERS
2.2.4. BARGAINING
POWER OF SUPPLIERS
2.2.5. COMPETITIVE
RIVALRY
2.3. COVID-19
AND ITS IMPACT ON DRUG DISCOVERY MARKET
2.4. PESTLE
OUTLOOK
2.5. REGULATORY
FRAMEWORK
2.6. VALUE
CHAIN OUTLOOK
2.7. MARKET
ATTRACTIVENESS INDEX
2.8. KEY
INSIGHT
2.9. MARKET
DRIVERS
2.9.1. GROWING
AGED POPULATION
2.9.2. TECHNOLOGICAL
ADVANCEMENTS
2.9.3. RISE
IN HEALTHCARE EXPENDITURE
2.9.4. SURGE
IN LIFESTYLE-ORIENTED DISEASES
2.10. MARKET RESTRAINTS
2.10.1. DELAY IN PRODUCT LAUNCHES
2.10.2. RESTRICTED GROWTH RATE DUE TO GENERIC DRUGS
2.11. MARKET OPPORTUNITIES
2.11.1. SIGNIFICANT INVESTMENT BY HEALTHCARE INDUSTRIES
IN IMPROVING BIG DATA ANALYTICAL CAPABILITIES
2.11.2. RISING DEMAND FOR SPECIALTY MEDICINES
2.12. MARKET CHALLENGES
2.12.1. STRINGENT GOVERNMENT REGULATIONS
3. DRUG
DISCOVERY MARKET OUTLOOK - BY DRUG TYPE
3.1. SMALL
MOLECULE DRUG
3.2. BIOLOGIC
DRUG
4. DRUG
DISCOVERY MARKET OUTLOOK - BY TECHNOLOGY
4.1. HIGH
THROUGHPUT SCREENING
4.2. BIOCHIPS
4.3. BIOINFORMATICS
4.4. PHARMACOGENOMICS
AND PHARMACOGENETICS
4.5. COMBINATORIAL
CHEMISTRY
4.6. NANOTECHNOLOGY
4.7. SPECTROSCOPY
4.8. METABOLOMICS
4.9. OTHER
TECHNOLOGIES
5. DRUG
DISCOVERY MARKET OUTLOOK - BY SERVICE
5.1. DRUG
METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES
5.2. CHEMICAL
SERVICES
5.3. BIOLOGICAL
SERVICES
5.4. OTHER
PHARMACEUTICAL SERVICES
6. DRUG
DISCOVERY INDUSTRY OUTLOOK - BY END-USER
6.1. RESEARCH
INSTITUTES
6.2. PHARMACEUTICAL
COMPANIES
6.3. CONTRACT
RESEARCH ORGANIZATIONS (CROS)
6.4. OTHER
END-USERS
7. DRUG
DISCOVER MARKET – EUROPE
7.1. COUNTRY
ANALYSIS
7.1.1. THE
UNITED KINGDOM
7.1.2. FRANCE
7.1.3. GERMANY
7.1.4. SPAIN
7.1.5. ITALY
7.1.6. RUSSIA
7.1.7. REST
OF EUROPE
8. COMPANY
PROFILES
8.1. 3M
COMPANY
8.2. ABBOTT
LABORATORIES INC
8.3. AGILENT
TECHNOLOGIES INC
8.4. ANTARES
PHARMA INC
8.5. ASTRAZENECA
PLC
8.6. BAYER AG
8.7. BECTON
DICKINSON & COMPANY (BD)
8.8. BOEHRINGER
INGELHEIM
8.9. ELI
LILY AND COMPANY
8.10. F HOFFMANN-LA ROCHE LTD
8.11. GLAXOSMITHKLINE LLC
8.12. JOHNSON & JOHNSON
8.13. MERCK & CO INC
8.14. NOVARTIS
8.15. PFIZER INC
8.16. SANOFI
9. RESEARCH
METHODOLOGY & SCOPE
9.1. RESEARCH
SCOPE & DELIVERABLES
9.1.1. OBJECTIVES
OF STUDY
9.1.2. SCOPE
OF STUDY
9.2. SOURCES
OF DATA
9.2.1. PRIMARY
DATA SOURCES
9.2.2. SECONDARY
DATA SOURCES
9.3. RESEARCH
METHODOLOGY
9.3.1. EVALUATION
OF PROPOSED MARKET
9.3.2. IDENTIFICATION
OF DATA SOURCES
9.3.3. ASSESSMENT
OF MARKET DETERMINANTS
9.3.4. DATA
COLLECTION
9.3.5. DATA
VALIDATION & ANALYSIS
TABLE 1 EUROPE DRUG DISCOVERY MARKET, BY COUNTRY, 2019-2028 ($
MILLION)
TABLE 2 EUROPE DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2019-2028 ($
MILLION)
TABLE 3 EUROPE DRUG DISCOVERY MARKET, BY DRUG TYPE, 2019-2028 ($
MILLION)
TABLE 4 EUROPE DRUG DISCOVERY MARKET, BY SERVICE, 2019-2028 ($
MILLION)
TABLE 5 EUROPE DRUG DISCOVERY MARKET, BY END-USER, 2019-2028 ($
MILLION)
TABLE 6 EUROPE DRUG DISCOVERY MARKET, BY COUNTRY, 2019-2028 ($
MILLION)
FIGURE 1 EUROPE DRUG DISCOVERY MARKET, BY REGION, 2019-2028
($ MILLION)
FIGURE 2 EUROPE DRUG DISCOVERY MARKET, BY SMALL
MOLECULE DRUG, 2019-2028 ($ MILLION)
FIGURE 3 EUROPE DRUG DISCOVERY MARKET, BY BIOLOGIC
DRUG, 2019-2028 ($ MILLION)
FIGURE 4 EUROPE DRUG DISCOVERY MARKET, BY HIGH
THROUGHPUT SCREENING, 2019-2028 ($ MILLION)
FIGURE 5 EUROPE DRUG DISCOVERY MARKET, BY BIOCHIPS,
2019-2028 ($ MILLION)
FIGURE 6 EUROPE DRUG DISCOVERY MARKET, BY
BIOINFORMATICS, 2019-2028 ($ MILLION)
FIGURE 7 EUROPE DRUG DISCOVERY MARKET, BY
PHARMACOGENOMICS AND PHARMACOGENETICS, 2019-2028 ($ MILLION)
FIGURE 8 EUROPE DRUG DISCOVERY MARKET, BY
COMBINATORIAL CHEMISTRY, 2019-2028 ($ MILLION)
FIGURE 9 EUROPE DRUG DISCOVERY MARKET, BY
NANOTECHNOLOGY, 2019-2028 ($ MILLION)
FIGURE 10 EUROPE DRUG DISCOVERY MARKET, BY
SPECTROSCOPY, 2019-2028 ($ MILLION)
FIGURE 11 EUROPE DRUG DISCOVERY MARKET, BY
METABOLOMICS, 2019-2028 ($ MILLION)
FIGURE 12 EUROPE DRUG DISCOVERY MARKET, BY OTHER
TECHNOLOGIES, 2019-2028 ($ MILLION)
FIGURE 13 EUROPE DRUG DISCOVERY MARKET, BY DRUG
METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES, 2019-2028 ($ MILLION)
FIGURE 14 EUROPE DRUG DISCOVERY MARKET, BY CHEMICAL
SERVICES, 2019-2028 ($ MILLION)
FIGURE 15 EUROPE DRUG DISCOVERY MARKET, BY BIOLOGICAL
SERVICES, 2019-2028 ($ MILLION)
FIGURE 16 EUROPE DRUG DISCOVERY MARKET, BY OTHER
PHARMACEUTICAL SERVICES, 2019-2028 ($ MILLION)
FIGURE 17 EUROPE DRUG DISCOVERY MARKET, BY RESEARCH
INSTITUTES, 2019-2028 ($ MILLION)
FIGURE 18 EUROPE DRUG DISCOVERY MARKET, BY
PHARMACEUTICAL COMPANIES, 2019-2028 ($ MILLION)
FIGURE 19 EUROPE DRUG DISCOVERY MARKET, BY CONTRACT
RESEARCH ORGANIZATIONS (CROS), 2019-2028 ($ MILLION)
FIGURE 20 EUROPE DRUG DISCOVERY MARKET, BY OTHER
END-USERS, 2019-2028 ($ MILLION)
FIGURE 21 THE UNITED KINGDOM DRUG DISCOVERY MARKET
2019-2028 ($ MILLION)
FIGURE 22 FRANCE DRUG DISCOVERY MARKET 2019-2028 ($
MILLION)
FIGURE 23 GERMANY DRUG DISCOVERY MARKET 2019-2028 ($
MILLION)
FIGURE 24 SPAIN DRUG DISCOVERY MARKET 2019-2028 ($
MILLION)
FIGURE 25 ITALY DRUG DISCOVERY MARKET 2019-2028 ($
MILLION)
FIGURE 26 RUSSIA DRUG DISCOVERY MARKET 2019-2028 ($
MILLION)
FIGURE 27 REST OF EUROPE DRUG DISCOVERY MARKET
2019-2028 ($ MILLION)